Illumina, Inc. (ILMN) Director Robert S. Epstein Sells 1,250 Shares
Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now directly owns 9,088 shares of the company’s stock, valued at $2,058,886.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Illumina, Inc. (NASDAQ ILMN) traded down $2.39 during mid-day trading on Wednesday, reaching $211.06. The company had a trading volume of 1,050,000 shares, compared to its average volume of 958,333. Illumina, Inc. has a 1 year low of $119.37 and a 1 year high of $230.72. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The stock has a market cap of $30,920.00, a P/E ratio of 62.41, a price-to-earnings-growth ratio of 3.53 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. During the same period in the previous year, the business earned $0.97 EPS. The firm’s revenue for the quarter was up 17.6% on a year-over-year basis. sell-side analysts predict that Illumina, Inc. will post 3.75 EPS for the current year.
ILMN has been the subject of a number of research analyst reports. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target for the company in a research note on Wednesday, August 9th. Barclays reaffirmed an “equal weight” rating and set a $150.00 target price on shares of Illumina in a research report on Wednesday, August 9th. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 target price (up from $207.00) on shares of Illumina in a research report on Tuesday, September 12th. Finally, Argus lifted their target price on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $201.98.
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after buying an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Illumina by 3.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after purchasing an additional 76,452 shares during the last quarter. Capital World Investors grew its stake in Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after purchasing an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after purchasing an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC purchased a new stake in Illumina during the 2nd quarter valued at about $211,584,000. Hedge funds and other institutional investors own 91.75% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) Director Robert S. Epstein Sells 1,250 Shares” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://theolympiareport.com/2017/12/06/illumina-inc-ilmn-director-robert-s-epstein-sells-1250-shares.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.